Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study) - Iwuji, Collins; Waters, Laura; Milinkovic, Ana; Orkin, Chloe; Fox, Julie; Post, Frank; Perry, Nicky; Bruce, Chloe; Dailey, Natalie; To, Ye; Bremner, Stephen; Churchill, Duncan; et al. (Virology Journal, 2025)